Khalil Asmar, VP of cardiometabolic health at Lilly UK & Ireland (l), and former England spin bowler Ashley Giles (r). Like ...

The Supreme Court of the US has ruled that the abortion pill mifepristone can continue to be prescribed remotely and ...

UK reimbursement authority NICE has recommended that the NHS in England can use AstraZeneca's Imfinzi as the first ...

Cardiac rhythm management is undergoing a significant shift. For decades, cardiac resynchronisation therapy has helped restore synchrony in patients with heart failure and electrical conduction ...

Biogen has decided to advance its tau-targeting Alzheimer's disease drug diranersen (BIIB080) into a phase 3 trial programme, despite a phase 2 trial missing its main efficacy measure. In the 18-month ...

Sanofi's oral BTK inhibitor tolebrutinib is heading towards an FDA decision in September as a potential treatment for multiple sclerosis (MS) after a priority review by the US regulator. Tolebrutinib ...

President Donald Trump's plan to introduce a most favoured nation (MFN) system of drug pricing controls is not quite what he first said it would be, according to a statement from the administration.

Regenxbio is pitching at FDA approval next year for its Duchenne muscular dystrophy (DMD) gene therapy RGX-202, after ...

It’s safe to say that AI has firmly captured the interest of decision-makers across the industry. But, as the space continues ...

Bladder cancer has been billed by AstraZeneca as a key growth area for its immunotherapy Imfinzi, an ambition that has now ...

The head-to-head rivalry between Novo Nordisk and Eli Lilly in oral GLP-1 agonists for weight loss has come to the fore this ...

Parallel reviews of new medicines by the UK's MHRA drug regulator and reimbursement authority NICE benefit industry more than patients and the NHS. That is the contention voiced by Huseyin Naci at the ...